4-(丙基磺酰基)苯胺 | 86810-78-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(丙基磺酰基)苯胺
• 英文名称: (4-Aminophenyl)-propyl-sulfon
• 英文别名: 4-(propane-1-sulfonyl)-aniline；4-Propylsulfon-anilin；4-(Propan-1-sulfonyl)-anilin；Propyl-(4-amino-phenyl)-sulfon；4-propylsulfonylaniline；4-(Propylsulfonyl)aniline
• CAS: 86810-78-8
• 化学式: C₉H₁₃NO₂S
• 分子量: 199.274
• InChiKey: UPYAKDAOBGDGJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2921420090

反应信息

• 作为反应物：
  描述：

  5-(1-(6-氯-5-硝基嘧啶-4-基)哌啶-4-基)-3-异丙基-1,2,4-恶二唑 、 4-(丙基磺酰基)苯胺 在 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.08h， 以26%的产率得到6-(4-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl)-5-nitro-N-(4-(propylsulfonyl)phenyl)-pyrimidin-4-amine
  参考文献：
  名称：

  Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119

  摘要：

  GPR119 is a rhodopsin-like GPCR expressed in pancreatic beta-cells and incretin releasing cells in the GI tract. As with incretins, GPR119 increase,; cAMP levels in these cell types. thus making it a highly attractive potential target for the treatment of diabetes. The discovery of the first reported potent agonist of GPR119, 2-fluoro-4-methanesulfonyl-phenyl)-{6-[4-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-1-yl]-5-nitro-pyrimidin-4-yl}-amine (8g, AR231453), is described starting from an initial inverse agonist screening hit. Compound 8g showed in vivo activity in rodents and was active in an oral glucose tolerance test in mice following oral administration.

  DOI：

  10.1021/jm8006867
• 作为产物：
  描述：

  对乙酰氨基苯亚磺酸 在 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 28.0h， 生成 4-(丙基磺酰基)苯胺
  参考文献：
  名称：

  合成烷基芳基，环烷基和芳基-（4-氨基苯基）-磺化剂的方法

  摘要：

  某些烷基-，环烷基-和芳基-（4-氨基苯基）砜的合成

  DOI：

  10.1002/hlca.19830660407

文献信息

• Thiazolopyrimidine modulators of TRPV1
  申请人：Branstetter Bryan James

  公开号：US20080004253A1

  公开（公告）日：2008-01-03

  Certain TRPV1-modulating thiazolopyrimidine compounds are described. The compounds may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by TRPV1 activity, such as pain, arthritis, itch, cough, asthma, or inflammatory bowel disease.

  描述了某些调节TRPV1的噻唑吡咯啉化合物。这些化合物可以用于制备药物组合物和治疗由TRPV1活性介导的疾病状态、紊乱和病况的方法，如疼痛、关节炎、瘙痒、咳嗽、哮喘或炎症性肠病。
• SULFONE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS A MEDICINE
  申请人：Lücking Ulrich

  公开号：US20110251222A1

  公开（公告）日：2011-10-13

  The invention relates to sulphone-substituted anilinopyrimidine derivatives of the formula (I), to its preparation processes, and to its use as medicament for treating various diseases.

  该发明涉及公式（I）的磺酮取代苯胺吡啶衍生物，其制备方法，以及作为治疗各种疾病的药物的用途。
• Vinylcarboxylic acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05545630A1

  公开（公告）日：1996-08-13

  Compounds of the formula ##STR1## wherein R.sub.1 is C.sub.3 -C.sub.8 cycloalkyl, halo-C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl-C.sub.1 -C.sub.6 alkyl, halo-C.sub.3 -C.sub.8 cycloalkyl-C.sub.1 -C.sub.6 alkyl, --Si(R.sub.3).sub.3, --S--R.sub.4, --SO.sub.2 --R.sub.6 or --CO--R.sub.9 ; R.sub.2 is halogen, C.sub.1 -C.sub.4 alkyl or CF.sub.3, the substituents R.sub.2 being identical or different when n is 2; R.sub.3 each independently of the others is C.sub.1 -C.sub.6 alkyl, halo-C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy or phenyl; R.sub.4 is aryl or heteroaryl each of which is unsubstituted or substituted; R.sub.6 is unsubstituted or substituted C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.1 -C.sub.20 alkoxy, C.sub.2 -C.sub.6 alkenyloxy, C.sub.2 -C.sub.6 alkynyloxy, C.sub.1 -C.sub.4 alkylthio, aryl, aryloxy or arylthio, or is optionally substituted amino; R.sub.9 is hydroxy, unsubstituted or substituted C.sub.1 -C.sub.10 alkyl, C.sub.2 -C.sub.6 alkenyl, C.sub.2 -C.sub.6 alkynyl, C.sub.3 -C.sub.8 cycloalkyl, aryl or aryloxy, or is optionally substituted amino; R.sub.12 is hydrogen or unsubstituted or substituted C.sub.1 -C.sub.10 alkyl; m is 1, 3, 5, 7, 9 or 11; n is 0, 1 or 2; X is fluorine or chlorine; and Y is hydrogen, fluorine or methyl; in free form or in salt form, can be used as pesticides and can be prepared in a manner known per se.

  化合物的化学式为##STR1##其中R.sub.1为C.sub.3-C.sub.8环烷基，卤代C.sub.3-C.sub.8环烷基，C.sub.3-C.sub.8环烷基-C.sub.1-C.sub.6烷基，卤代C.sub.3-C.sub.8环烷基-C.sub.1-C.sub.6烷基，--Si（R.sub.3）.sub.3，--S--R.sub.4，--SO.sub.2--R.sub.6或--CO--R.sub.9；R.sub.2为卤素，C.sub.1-C.sub.4烷基或CF.sub.3，当n为2时，取代基R.sub.2相同或不同；R.sub.3各自独立为C.sub.1-C.sub.6烷基，卤代C.sub.1-C.sub.6烷基，C.sub.1-C.sub.6烷氧基或苯基；R.sub.4为芳基或杂芳基，未取代或取代；R.sub.6为未取代或取代的C.sub.1-C.sub.10烷基，C.sub.2-C.sub.6烯基，C.sub.2-C.sub.6炔基，C.sub.1-C.sub.20烷氧基，C.sub.2-C.sub.6烯氧基，C.sub.2-C.sub.6炔氧基，C.sub.1-C.sub.4烷硫基，芳基，芳氧基或芳硫基，或为可选取代的氨基；R.sub.9为羟基，未取代或取代的C.sub.1-C.sub.10烷基，C.sub.2-C.sub.6烯基，C.sub.2-C.sub.6炔基，C.sub.3-C.sub.8环烷基，芳基或芳氧基，或为可选取代的氨基；R.sub.12为氢或未取代或取代的C.sub.1-C.sub.10烷基；m为1、3、5、7、9或11；n为0、1或2；X为氟或氯；Y为氢、氟或甲基；以自由形式或盐形式可用作杀虫剂，并可按已知的方法制备。
• Oxadiazole Derivative as Dgat Inhibitors
  申请人：Birch Martin Alan

  公开号：US20080096874A1

  公开（公告）日：2008-04-24

  Compounds of formula (I), and salts and pro-drugs thereof: Formula (I) wherein for example R 1 is optionally substituted aryl or heteroaryl; Y is a linking group selected from, for example, a direct bond, and a (substituted) alkyl chain; R 2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; are described. Processes to make such compounds and their use as DGAT inhibitors, for example in the treatment of obesity, are also described.

  式（I）的化合物，以及其盐和前药：其中，例如R1是可选取代芳基或杂环芳基；Y是选择自直接键和（取代）烷基链等的连接基；R2是可选取代芳基、可选取代环烷基或可选取代杂环基团。还描述了制备此类化合物的方法及其作为DGAT抑制剂的用途，例如在肥胖症的治疗中。
• Pyrazolo[3,4-b]Pyridine Compounds, and their Use as Phosphodiesterase Inhibitors
  申请人：ALLEN David George

  公开号：US20080175914A1

  公开（公告）日：2008-07-24

  The invention relates to a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-4 alkyl, C 1-3 fluoroalkyl, —CH 2 CH 2 OH or —CH 2 CH 2 CO 2 C 1-2 alkyl; R 2 is a hydrogen atom (H), methyl or C 1 fluoroalkyl; R 3 is optionally substituted C 3-8 cycloalkyl or optionally substituted mono-unsaturated-C 5-7 cycloalkenyl or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc); in which n 1 and n 2 independently are 1 or 2; and in which Y is O, S, SO 2 , or NR 10 ; or R 3 is a bicyclic group (dd) or (ee): and wherein X is NR 4 R 5 or OR 5a . The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE 4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis.

  本发明涉及公式（I）的化合物或其盐： 其中： R1是C1-4烷基，C1-3氟烷基，-CH2CH2OH或-CH2CH2CO2C1-2烷基; R2是氢原子（H），甲基或C1氟烷基; R3是可选取代的C3-8环烷基或可选取代的单不饱和C5-7环烯基或亚公式（aa），（bb）或（cc）的可选取代的杂环基; 其中n1和n2独立地为1或2; Y是O，S，SO2或NR10; 或R3是双环基（dd）或（ee）： 其中X是NR4R5或OR5a。 该化合物是磷酸二酯酶（PDE）抑制剂，特别是PDE4抑制剂。本发明还提供了公式（I）的化合物或其药学上可接受的盐的用途，用于制造治疗和/或预防哺乳动物，如人类的炎症性和/或过敏性疾病的药物，例如慢性阻塞性肺疾病（COPD），哮喘或过敏性鼻炎。